Indolent Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Q
Recruiting
  • Follicular Lymphoma
  • +7 more
  • Louisville, Kentucky
  • +4 more
2022-03-11
Mar 11, 2022
U
Active, not recruiting
  • Non Hodgkin Lymphoma
  • +8 more
  • Miami, Florida
  • +2 more
2022-03-08
Mar 8, 2022
T
Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
2022-03-22
Mar 22, 2022
N
Recruiting
  • Lymphoma, Non-Hodgkin
  • +9 more
  • NKX019
  • Denver, Colorado
  • +6 more
2022-01-19
Jan 19, 2022
T
Recruiting
  • Indolent Lymphoma
  • vegan diet and lifestyle changes
  • Tel Aviv, Israel
    Tel-Aviv Sourasky Medical Center
2021-07-05
Jul 5, 2021
S
Recruiting
  • B-cell Lymphoma
  • +7 more
  • Birmingham, Alabama
  • +20 more
2020-10-14
Oct 14, 2020
U
Completed
  • Lymphoma
  • +3 more
  • Tucson, Arizona
    The University of Arizona Cancer Center
2019-12-16
Dec 16, 2019
N
Unknown status
  • Indolent Lymphoma
  • Ledipasvir and sofosbuvir
  • (no location specified)
2017-08-23
Aug 23, 2017
G
Terminated
  • Indolent Lymphoma
  • Therapy with Rituximab, Gemcitabine and Oxaliplatin
  • Ludwigshafen, Germany
    Klinikum Ludwigshafen
2015-08-17
Aug 17, 2015
S
Completed
  • Hodgkin Lymphoma
  • +2 more
  • Omaha, Nebraska
  • +4 more
2012-04-19
Apr 19, 2012
T
Unknown status
  • Soft Tissue Sarcomas
  • +9 more
    • Tel Aviv, Israel
      Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center
    2008-05-30
    May 30, 2008